Compare BioNano Genomics Inc (BNGO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.77M), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.47. Which is the better fit depends on your goals.
| BNGO | VCIT | |
|---|---|---|
Market Cap | $13.77M | — |
Sector | Health | Fixed Income |
52-Week High | $4.92 | $84.82 |
52-Week Low | $1.06 | $81.07 |
Enterprise Value | $16.38M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.18, down 0.84% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company shows improving financial trends, with net losses narrowing significantly from -$232M in 2023 to -$26M in 2025, and recent earnings beats. Revenue remains steady around $29M, while analyst sentiment is positive with 57% buy ratings.
Outlook: BNGO presents a speculative opportunity with strong analyst support and improving fundamentals, but risks include persistent negative cash flows, high operating costs, and competitive pressures in genomics. The stock's low valuation multiples may attract value investors, yet profitability remains a key hurdle.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.11% daily gain. Technical indicators show a bearish trend from moving averages but neutral oscillators, with all key support and resistance levels clustered around $81. Recent news highlights its competitive 0.03% expense ratio and approximately 4.9% yield compared to peers like iShares funds, emphasizing its appeal for income-focused investors in the current fixed-income landscape.
The outlook for VCIT is shaped by its low-cost access to investment-grade corporate bonds, offering higher yield potential than Treasury alternatives but with moderate volatility. Key risks include interest rate sensitivity and economic shifts affecting corporate credit. Analyst sentiment is generally positive due to its yield advantage and cost efficiency, though investors should weigh credit risk against stability needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
